Literature DB >> 11438519

HIV Nef-mediated cellular phenotypes are differentially expressed as a function of intracellular Nef concentrations.

X Liu1, J A Schrager, G D Lange, J W Marsh.   

Abstract

Nef is a regulatory protein encoded by the genome of both human and simian immunodeficiency virus. Its expression in T cells leads to CD4 and major histocompatibility complex class I modulation and either enhancement or suppression of T cell activation. How this viral protein achieves multiple and at times opposing activities has been unclear. Through direct measurements of Nef and the Nef-GFP fusion protein, we find that these events are mediated by different Nef concentrations. Relative to the intracellular concentration that down-modulates surface CD4, an order of magnitude increase in Nef-GFP expression is required for a comparable modulation of major histocompatibility complex class I, and a further 3-fold increase is necessary to suppress T cell activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438519     DOI: 10.1074/jbc.M101025200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Rebekah I Fleis; Chris G Przybycin; Kathleen L Collins
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

3.  HIV Nef-mediated major histocompatibility complex class I down-modulation is independent of Arf6 activity.

Authors:  Jakob E Larsen; Ramiro H Massol; Thomas J F Nieland; Tomas Kirchhausen
Journal:  Mol Biol Cell       Date:  2003-11-14       Impact factor: 4.138

4.  CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

5.  Rev-dependent indicator T cell line.

Authors:  Yuntao Wu; Margaret H Beddall; Jon W Marsh
Journal:  Curr HIV Res       Date:  2007-07       Impact factor: 1.581

6.  Simian immunodeficiency virus Nef protein delays the progression of CD4+ T cells through G1/S phase of the cell cycle.

Authors:  Thomas Ndolo; Navdeep K Dhillon; Hau Nguyen; Moraima Guadalupe; Maria Mudryj; Satya Dandekar
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Nef-mediated inhibition of NFAT following TCR stimulation differs between HIV-1 subtypes.

Authors:  Lisa Naidoo; Zinhle Mzobe; Steven W Jin; Erasha Rajkoomar; Tarylee Reddy; Mark A Brockman; Zabrina L Brumme; Thumbi Ndung'u; Jaclyn K Mann
Journal:  Virology       Date:  2019-02-21       Impact factor: 3.616

8.  Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.

Authors:  Thomas D Zaikos; Mark M Painter; Nadia T Sebastian Kettinger; Valeri H Terry; Kathleen L Collins
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

9.  Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis.

Authors:  Edward A Acheampong; Cassandra Roschel; Muhammad Mukhtar; Alagarsamy Srinivasan; Mohammad Rafi; Roger J Pomerantz; Zahida Parveen
Journal:  Virol J       Date:  2009-10-30       Impact factor: 4.099

10.  Impaired Nef function is associated with early control of HIV-1 viremia.

Authors:  Xiaomei T Kuang; Xiaoguang Li; Gursev Anmole; Philip Mwimanzi; Aniqa Shahid; Anh Q Le; Louise Chong; Hua Qian; Toshiyuki Miura; Tristan Markle; Bemuluyigza Baraki; Elizabeth Connick; Eric S Daar; Heiko Jessen; Anthony D Kelleher; Susan Little; Martin Markowitz; Florencia Pereyra; Eric S Rosenberg; Bruce D Walker; Takamasa Ueno; Zabrina L Brumme; Mark A Brockman
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.